ArticleBreast cancer (Dove Medical Press)2025

Management Strategies and Outcomes in HR+/HER2- Metastatic Breast Cancer Receiving CDK4/6 Inhibitors and Subsequent Therapies.

Katarzyna Pogoda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.